Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹24 Cr
Revenue (TTM)
₹295 Cr
Net Profit (TTM)
₹2 Cr
ROE
4.7 %
ROCE
9.6 %
P/E Ratio
11.6
P/B Ratio
9.3
Industry P/E
48.17
EV/EBITDA
8.6
Div. Yield
0 %
Debt to Equity
0
Book Value
₹4.7
EPS
₹3.8
Face value
10
Shares outstanding
5,468,300
CFO
₹0.52 Cr
EBITDA
₹-0.17 Cr
Net Profit
₹-0.17 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Rubra Medicaments
| -61.9 | -34.0 | -63.7 | 224.2 | -- | 77.9 | -- |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Rubra Medicaments
| 793.4 | 168.0 | 3.1 | 11.1 | 70.3 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Rubra Medicaments
|
43.5 | 23.8 | 294.6 | 2.1 | 0.9 | 163.8 | 11.6 | 9.3 |
| 2,791.2 | 34,833.3 | 5,201.6 | 1,014.6 | 22.9 | 25 | 34.3 | 7.6 | |
| 1,547.6 | 29,300.1 | 8,850.1 | 894.8 | 15.2 | 19.8 | 33.7 | 5.9 | |
| 1,249.1 | 5,421.5 | 6,020.3 | 132.1 | 3.2 | 6.8 | 48.1 | 3.0 | |
| 1,961.1 | 31,456.7 | 4,193.0 | 753.8 | 22.7 | 20.8 | 41.7 | 7.9 | |
| 30.5 | 13.4 | 25.3 | 0.1 | 0.4 | 2.5 | 117.7 | 2.8 | |
| 24.1 | 30.1 | 16.0 | -4.4 | -58.4 | -3.7 | -- | 0.3 | |
| 33.1 | 20.7 | 4.6 | 0.4 | 1.7 | 4 | 53.2 | 2.1 | |
| 1.9 | 7.6 | 110.0 | -0.2 | 0.0 | -3.5 | -- | 1.6 | |
| 0.3 | 30.9 | 386.8 | 35.4 | 11.1 | 29.9 | 0.9 | 0.2 |
No Review & Analysis are available.
Rubra Medicaments Limited engages in the trade of pharmaceuticals, and other medical and surgical products in India. The company was incorporated in 1991 and is based in Mumbai, India.
Incorporated
1991
Chairman
--
Managing Director
Shubham Chaudhary
Headquarters
Nashik, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Rubra Medicaments Ltd is ₹43.51 (BSE) as of 02-Apr-2026 IST. Rubra Medicaments Ltd has given a return of 224.22% in the last 1 years.
The P/E ratio of Rubra Medicaments Ltd is 11.61 times as on 02-Apr-2026, a 76 discount to its peers’ median range of 48.17 times.
The P/B ratio of Rubra Medicaments Ltd is 9.34 times as on 02-Apr-2026, a 3492 premium to its peers’ median range of 0.26 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
275.35
|
12.53
|
|
2024
|
178.90
|
10.14
|
|
2023
|
0.00
|
0.00
|
|
2022
|
0.00
|
6.62
|
|
2021
|
234.95
|
4.72
|
The 52-week high and low of Rubra Medicaments Ltd are Rs 144.40 and Rs 14.07 as of 02-Apr-2026.
Rubra Medicaments Ltd has a market capitalisation of ₹ 24 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Rubra Medicaments Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-2.29
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.